PD-1/PD-L1 Cancer Immunotherapeutics Reshape Tumor Microenvironment - Clinical Evidence and Molecular Mechanisms for AI-based Precision Medicine. [PDF]
Clin Rev Allergy ImmunolLin YY +5 more
europepmc +1 more source
Beyond the hype: Antibody-Drug Conjugates are advancing faster than our clinical strategy. [PDF]
PLoS MedNotini G +3 more
europepmc +1 more source
Triple Negative Breast Cancer With Choroidal Metastasis Responsive to Sacituzumab Govitecan and Radiation Therapy. [PDF]
Cancer Rep (Hoboken)Nafissi N +4 more
europepmc +1 more source
Double metastatic cancer with lung and urothelial carcinoma responding to enfortumab vedotin: a case report and review of the literature. [PDF]
J Med Case RepRavoire M, Vazquez L.
europepmc +1 more source
Spatial Multiomics Reveal Insights Into ADC Efficacy. [PDF]
Eur J ImmunolGoni O +4 more
europepmc +1 more source
Response to trastuzumab-deruxtecan in metastatic triple-negative breast cancer with both HER2 mutation and low expression. [PDF]
Einstein (Sao Paulo)Amarger CD +8 more
europepmc +1 more source
Evaluating Radiotheranostic Targets for Endometrial Cancer. [PDF]
J Nucl MedSebastiano J +7 more
europepmc +1 more source
Exploring the Interplay Between Radioimmunoconjugates and Fcγ Receptors in Genetically Engineered Mouse Models of Cancer. [PDF]
ACS Pharmacol Transl SciRodriguez C +8 more
europepmc +1 more source
FDA and EMA approval of datopotamab-deruxtecan: A paradigm shift in breast cancer drug evaluation? [PDF]
BreastOrlandi A.
europepmc +1 more source
Trojan horses at leptomeningeal cellular gates: Antibody-drug conjugates deliver cytotoxic payloads. [PDF]
MedNikanjam M, Kurzrock R.
europepmc +1 more source